Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Search in posts
Search in pages
Filter by Categories
Allied Health Professionals’ Corner
Author Reply
Book Review
Brief Communication
Case Report
Case Series
Clinical Case Report
Clinicopathological Conference
Commentary
Corrigendum
Editorial
Editorial – World Kidney Day 2016
Editorial Commentary
Erratum
Foreward
Guideline
Guidelines
Image in Nephrology
Images in Nephrology
In-depth Review
Letter to Editor
Letter to the Editor
Letter to the Editor – Authors’ reply
Letters to Editor
Literature Review
Nephrology in India
Notice of Retraction
Obituary
Original Article
Perspective
Research Letter
Retraction Notice
Review
Review Article
Short Review
Special Article
Special Feature
Special Feature - World Kidney Day
Systematic Review
Technical Note
Varia
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Search in posts
Search in pages
Filter by Categories
Allied Health Professionals’ Corner
Author Reply
Book Review
Brief Communication
Case Report
Case Series
Clinical Case Report
Clinicopathological Conference
Commentary
Corrigendum
Editorial
Editorial – World Kidney Day 2016
Editorial Commentary
Erratum
Foreward
Guideline
Guidelines
Image in Nephrology
Images in Nephrology
In-depth Review
Letter to Editor
Letter to the Editor
Letter to the Editor – Authors’ reply
Letters to Editor
Literature Review
Nephrology in India
Notice of Retraction
Obituary
Original Article
Perspective
Research Letter
Retraction Notice
Review
Review Article
Short Review
Special Article
Special Feature
Special Feature - World Kidney Day
Systematic Review
Technical Note
Varia
View/Download PDF

Translate this page into:

Letter to the Editor
ARTICLE IN PRESS
doi:
10.25259/IJN_513_2024

Challenges and Considerations in Metformin Use for ADPKD: A Commentary on Recent Findings

Department of Pharmacology, PGIMER, Chandigarh, India
Center for Global Health Research, Saveetha Medical College and Hospital, Saveetha Institute of Medical and Technical Sciences, Saveetha University, Chennai, India
Department of Biotechnology, Graphic Era (Deemed to be University), Dehradun, India
Department of Pediatrics, Sanjeevani Hospital, Kalyanpur, Siraha, Nepal
University Center for Research and Development, Chandigarh University, Punjab, India

Corresponding author: Amol N Patil, Department of Pharmacology, PGIMER, Chandigarh, India. E-mail: patil.amol@pgimer.edu.in

Licence
This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

How to cite this article: Patil AN, Singh MP, Rawat P, Sah S, Satapathy P. Challenges and Considerations in Metformin Use for ADPKD: A Commentary on Recent Findings. Indian J Nephrol. doi: 10.25259/IJN_513_2024

Dear Editor,

We are writing to provide our perspective on the recently published study by Venkatasubramanian et al.1 The authors’ investigation into the efficacy of metformin in nondiabetic patients with autosomal dominant polycystic kidney disease (ADPKD) adds to the growing body of literature exploring novel therapeutic avenues for this challenging condition. The study’s findings, particularly the observation that metformin did not significantly slow the progression of the disease as measured by changes in estimated glomerular filtration rate (eGFR) and height-adjusted total kidney volume (htTKV), are consistent with previous trials such as the Trial of Administration of Metformin in Polycystic Kidney Disease (TAME-PKD) study and the work of Brosnahan et al.2 However, this study stands out for its focus on a low-risk cohort (Mayo Class 1A-C) and its attempt to elucidate metformin’s potential renoprotective effects in a more uniform population with well-preserved renal function at baseline.1 The metformin’s proteinuria-reducing capacity and protection from renal cancers in the diabetic population is mentioned due to its vascular endothelial growth factor (VEGF) induction pathway.35 Besides that, type 2 diabetes patients experience renoprotective effects in terms of eGFR change with the flozin group of drugs.6 The readers couldn’t see the benefits of metformin intervention due to baseline differences during the recruitment. The study’s results raise important questions about the role of metformin in ADPKD management, particularly regarding its long-term impact and the challenges in maintaining therapeutic doses in this population. Only 46.1% of participants in the metformin arm tolerated the total dose, highlighting the need for further research into optimizing dosing regimens, possibly through personalized medicine approaches that account for individual tolerability and disease characteristics.

Moreover, the study’s findings underscore the potential limitations of short-term follow-up in capturing the full extent of metformin’s effects. The nonsignificant differences observed may be a function of the study’s duration rather than the inefficacy of the intervention. Therefore, as the authors suggest, extended follow-up studies with larger sample sizes are crucial to determine whether metformin could offer meaningful clinical benefits in the ADPKD population.1

In conclusion, while this study adds valuable data to the ongoing discourse on metformin’s role in ADPKD, it also highlights the need for further investigation. Future studies should focus on more extended follow-up periods, personalized dosing strategies, and a more comprehensive assessment of patient-reported outcomes to understand the potential of metformin in this context.

Conflicts of interest

There are no conflicts of interest.

References

  1. , , , , , . Metformin versus standard of care in patients with autosomal dominant polycystic kidney disease – A randomized control trial. Indian J Nephrol :1-7.
    [Google Scholar]
  2. , , , , , , , , . Metformin therapy in autosomal dominant polycystic kidney disease: A feasibility study. Am J Kidney Dis. 2022;79(4):518-526.
    [CrossRef] [PubMed] [PubMed Central] [Google Scholar]
  3. , , , , , , et al. Metformin reduces proteinuria in spontaneously hypertensive rats by activating the HIF-2α-VEGF-A pathway. Eur J Pharmacol. 2021;891:173731.
    [CrossRef] [PubMed] [Google Scholar]
  4. , , , , , , et al. Impact of metformin on cardiovascular and kidney outcome based on kidney function status in type 2 diabetic patients: A multicentric, retrospective cohort study. Sci Rep. 2024;14:2081.
    [CrossRef] [PubMed] [PubMed Central] [Google Scholar]
  5. , , , , , . A story of metformin-butyrate synergism to control various pathological conditions as a consequence of gut microbiome modification: Genesis of a wonder drug? Pharmacol Res. 2017;117:103-28.
    [CrossRef] [PubMed] [Google Scholar]
  6. , , , , , , et al. Dose-dependent renoprotection efficacy of sglt2 inhibitors in type 2 diabetes: Systematic review and network meta-analysis. Acta Diabetol. 2023;60:1311-31.
    [CrossRef] [PubMed] [PubMed Central] [Google Scholar]

Fulltext Views
192

PDF downloads
170
View/Download PDF
Download Citations
BibTeX
RIS
Show Sections